• While most fusion startups are racing to generate electricity, Shine Technologies is taking a different route by using fusion today to produce high-value medical isotopes for cancer treatment. The idea is simple: start where fusion actually makes economic sense now, selling to premium medical markets instead of chasing lower-value electricity too early.

• Backed by a new $240 million funding round, Shine plans to scale isotope production first, then apply the same technology to recycling long-lived nuclear waste before eventually entering power generation down the road. It is a step-by-step commercialization strategy that turns fusion from a distant moonshot into something useful and revenue-generating today.